Liraglutide vs Survodutide
A once-daily GLP-1 receptor agonist; an earlier acylated analog. A dual glucagon and GLP-1 receptor agonist — the co-agonist that skips GIP and aims at the liver. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Liraglutide | Survodutide BI 456906 | |
|---|---|---|
| Also known as | Victoza, Saxenda | — |
| Type | Analog | Analog |
| Evidence | Established | Investigational |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | GLP-1 receptor agonist (acylated, 31 aa) | Glucagon/GLP-1 dual receptor agonist (acylated peptide) |
| Receptor / target | GLP-1 receptor (GLP-1R) | Glucagon receptor (GCGR) + GLP-1 receptor |
| Molecular weight | ~3,751.2 Da | ≈4,800 Da |
| Half-life | engineered for once-weekly dosing | |
| Based on | Glucagon-like peptide-1 | Glucagon-like peptide-1 |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Liraglutide and Survodutide?
- Liraglutide is an engineered analog based on Glucagon-like peptide-1; Survodutide is an engineered analog based on Glucagon-like peptide-1. Liraglutide signals at GLP-1 receptor (GLP-1R); Survodutide signals at Glucagon receptor (GCGR) + GLP-1 receptor.
- How do the half-lives of Liraglutide and BI 456906 compare?
- The reported circulating half-life of Liraglutide is ~13 h; Survodutide is engineered for once-weekly dosing. These are reference values for the native or representative form — educational only, not dosing advice.
- Is Liraglutide the same as Victoza?
- Victoza, Saxenda are brand names of Liraglutide. This comparison describes the molecules, not branded products.
Prefer the other order? Survodutide vs Liraglutide. Or open the interactive comparison tool to add more molecules.